InfuSystems Holdings, Inc.
INFU Healthcare Medical Devices
InfuSystems Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $143.4 million, up 6.36% from fiscal 2024. In the quarter to June 2026, revenue grew 2.59%, EPS grew 33.3%, free cash flow fell 66.5% and total debt fell 22.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow INFU
InfuSystems Holdings, Inc. (INFU) Piotroski F-score
InfuSystems Holdings, Inc.'s Piotroski F-score for fiscal 2025 is 8 out of 9: 8 of nine tests of profitability, leverage and efficiency passed, up from 7 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 8 | 1.00 |
| FY2024 | 7 | 0.00 |
| FY2023 | 7 | 2.00 |
| FY2022 | 5 | 1.00 |
| FY2021 | 4 | (3.00) |
| FY2020 | 7 | 0.00 |
| FY2019 | 7 | 2.00 |
| FY2018 | 5 | 1.00 |
| FY2017 | 4 | 0.00 |
| FY2016 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 6.49% | 2.27% | Pass | 1 |
| Positive operating cash flow | 24.41m | 20.46m | Pass | 1 |
| Rising return on assets | 6.49% | 2.27% | Pass | 1 |
| Cash flow above net income | 17.78m | 18.11m | Pass | 1 |
| Falling long-term leverage | 0.19 | 0.23 | Pass | 1 |
| Rising current ratio | 1.80 | 1.82 | Fail | 0 |
| No new shares issued | 20,658,000 | 21,272,000 | Pass | 1 |
| Rising gross margin | 55.98% | 52.20% | Pass | 1 |
| Rising asset turnover | 1.41 | 1.31 | Pass | 1 |
| Piotroski F-score | Strong — most fundamentals improved | 8 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| INFU InfuSystems Holdings, Inc. | 8 |
| ELMD Electromed, Inc. compare | 8 |
| CLPT ClearPoint Neuro, Inc. compare | 4 |
| LAB Standard BioTools Inc. compare | 4 |
| CATX Perspective Therapeutics, Inc. compare | 3 |
| RCEL Avita Medical Inc. compare | 3 |
| TLSI TriSalus Life Sciences, Inc. compare | 3 |
| TMCI Treace Medical Concepts, Inc. compare | 2 |
| QSI Quantum-Si Incorporated compare | 2 |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover